- Home
- FOXA vs BIIB Comparison
FOXA vs BIIB Comparison
Compare FOXA & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOXA
- BIIB
- Stock Information
- Founded
- FOXA 2018
- BIIB 1978
- Country
- FOXA United States
- BIIB United States
- Employees
- FOXA 10200
- BIIB N/A
- Industry
- FOXA Broadcasting
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- FOXA Industrials
- BIIB Health Care
- Exchange
- FOXA Nasdaq
- BIIB Nasdaq
- Market Cap
- FOXA 22.6B
- BIIB 25.1B
- IPO Year
- FOXA N/A
- BIIB 1991
- Fundamental
- Price
- FOXA $49.53
- BIIB $146.47
- Analyst Decision
- FOXA Buy
- BIIB Buy
- Analyst Count
- FOXA 18
- BIIB 26
- Target Price
- FOXA $47.00
- BIIB $248.00
- AVG Volume (30 Days)
- FOXA 4.4M
- BIIB 1.7M
- Earning Date
- FOXA 02-05-2025
- BIIB 02-11-2025
- Dividend Yield
- FOXA 1.07%
- BIIB N/A
- EPS Growth
- FOXA 103.10
- BIIB 10.05
- EPS
- FOXA 4.07
- BIIB 11.06
- Revenue
- FOXA $14,337,000,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- FOXA $13.50
- BIIB N/A
- Revenue Next Year
- FOXA N/A
- BIIB N/A
- P/E Ratio
- FOXA $12.17
- BIIB $13.24
- Revenue Growth
- FOXA N/A
- BIIB N/A
- 52 Week Low
- FOXA $28.29
- BIIB $145.07
- 52 Week High
- FOXA $50.63
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- FOXA 68.91
- BIIB 24.17
- Support Level
- FOXA $46.06
- BIIB $148.60
- Resistance Level
- FOXA $50.63
- BIIB $154.24
- Average True Range (ATR)
- FOXA 1.00
- BIIB 3.71
- MACD
- FOXA 0.18
- BIIB -0.37
- Stochastic Oscillator
- FOXA 77.30
- BIIB 7.48
About FOXA Fox Corporation
Fox operates in two segments: cable networks and television. Cable networks primarily includes Fox News, Fox Business, and several pay-TV sports stations. Television primarily includes the Fox broadcast network, 29 owned and operated local television stations, of which 18 are affiliated with the Fox network, and streaming platform Tubi, which is not subscription-based and is completely ad-supported. Fox effectively sold most of its entertainment assets to Disney in 2019, so it no longer creates entertainment content and relies heavily on live news and sports, with nearly all tied to the pay-TV bundle. The Murdoch family controls Fox.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.